NSP6 inhibits the production of ACE2-containing exosomes to promote SARS-CoV-2 infectivity.
Xi LvRan ChenTaizhen LiangHaojie PengQiannan FangShiqi XiaoSen LiuMeilin HuFei YuLixue CaoYiwen ZhangTing PanZhihui XiYao DingLinyuan FengTao ZengWenjing HuangHui ZhangXiancai MaPublished in: mBio (2024)
The outbreak of coronavirus disease 2019 (COVID-19) severely endangers global public health. The efficacy of vaccines and antibodies declined with the rapid emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutants. Angiotensin-converting enzyme 2-containing exosomes (ACE2-exos) therapy exhibits a broad neutralizing activity, which could be used against various viral mutations. Our study here revealed that SARS-CoV-2 nonstructural protein 6 inhibited the production of ACE2-exos, thereby promoting viral infection to the adjacent bystander cells. The identification of a new target for blocking SARS-CoV-2 depends on fully understanding the virus-host interaction networks. Our study sheds light on the mechanism by which the virus resists the host exosome defenses, which would facilitate the study and design of ACE2-exos-based therapeutics for COVID-19.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- coronavirus disease
- angiotensin converting enzyme
- public health
- angiotensin ii
- stem cells
- mesenchymal stem cells
- small molecule
- induced apoptosis
- single cell
- signaling pathway
- cell death
- zika virus
- cell cycle arrest
- cell therapy
- bone marrow
- endoplasmic reticulum stress
- protein protein